Hemophilia A and B involve deficiencies in coagulation factors VIII and IX, with traditional treatments requiring frequent infusions. Nonfactor therapies, including Hemlibra and rebalancing agents, ...
SurvivorNet on MSN
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
Repeated insulin shots at the same site can seed amyloid; consider this diagnosis if absorption seems erratic or glucose control worsens with a persistent lump.
Zacks Investment Research on MSN
KRMD submits 510(k) to use FreedomEDGE system with oncology biologic
KORU Medical Systems, Inc.KRMD recently announced that it has submitted a 510(k) premarket notification for FDA clearance to ...
Nodule and lipoma formation can occur rarely after an intramuscular influenza vaccination, particularly when administered ...
VKTX remains a Buy for its cheap FY2030 EV/Sales valuations of 2.28x, the strong clinical trial results exceeding legacy ...
The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.
The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...
Samsung Bioepis Co. Ltd. has announced the marketing approval of Ustekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO', ...
On Monday evening, the Food and Drug Administration approved Novo Nordisk’s high-dose oral formulation of semaglutide for ...
Intravenous (IV) and subcutaneous (SC) formulations each play important roles in modern oncology care, with distinct ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback